GVHD is a major complication following allogeneic hematopoietic SCT, and is associated with substantial morbidity and mortality. Based on the results of our previous clinical study with females treated with human chorionic gonadotropin (hCG) as preconditioning therapy for in vitro fertilization, we hypothesized that low-dose hCG stimulates indoleamine-2,3-dioxygenase (IDO), IL 10 and regulatory T cells (Treg), thereby suppressing clinical manifestations of chronic GVHD. Active chronic GVHD localized at skin, subcutaneous tissue, joints orgastrointestinal tract that was refractory or intolerant to glucocorticoid therapy improved substantially in 12 of 20 patients treated with hCG for 8 weeks (off-label), enabling a glucocorticoid dose reduction of 28% (average). Twelve of 19 patients with chronic GVHD of the skin responded to hCG therapy with a reduction of 25% (average) in their total skin score. HCG treatment increased IDO expression at median by sevenfold in peripheral mononuclear cells and IL10 levels in serum up to twofold at median from the pretreatment baseline. Further, an expansion of the Treg cell population was measured in one patient, which is also associated with the induction of tolerance. This novel application of low-dose hCG was well tolerated and is of clinical interest for GVHD treatment.
INTRODUCTION
Chronic GVHD is a major complication following allogeneic hematopoietic SCT and is associated with substantial morbidity and mortality. 1, 2 It is a systemic inflammatory disorder that reflects the lack of immune tolerance between donor-derived immunocompetent cells and host organs. Human chorionic gonadotropin (hCG) hormone is a naturally occurring hormone during pregnancy secreted by syncytiotrophoblasts of the placenta. We had previously observed that the rejection of transplanted skin was significantly delayed by hCG in a mouse skin transplant model and had also demonstrated that the tryptophan-catabolizing enzyme, indoleamine-2,3-dioxygenase gene expression (IDO), IL10 and T-regulatory cells (Tregs) increased significantly in females treated with hCG as preconditioning therapy for in vitro fertilization. 3 An immunosuppressive effect inducible by hCG has previously been demonstrated for IDO, in maternal-fetal acceptance, autoimmunity and GVHD. [4] [5] [6] [7] Further, IL10 and Tregs are also known factors to induce tolerance in the transplant setting. [4] [5] [6] [7] Therefore, given the low rate of adverse effects, we off-label used low dose of hCG to treat 20 patients as fourth-or fifth-line therapy with steroid-refractory or intolerant severe-grade chronic GVHD.
PATIENTS AND METHODS
This paper describes the compassionate use of hCG in 20 patients with severe or moderate chronic GVHD. The retrospective evaluation of this study and the compassionate use of hCG were approved by the institutional review board of the University Hospital of Duisburg-Essen. All patients fulfilled the following criteria or conditions: (1) patients must be diagnosed with severe or moderate grade of chronic GVHD according to National Institutes of Health consensus criteria (NIH). 8, 9 (2) Patients must have a glucocorticoid-refractory or intolerant chronic GVHD. Steroidrefractory GVHD was defined as disease clinically not responding to standard steroid therapy alone or in combination with other agents (1 mg/kg) according to a definition of Koc et al. 10 Steroid intolerance was assumed by the occurrence of non-acceptable steroid-induced side-effects or complications as uncontrolled diabetes, avascular necrosis, or systemic fungal or viral infections restricting the dose of steroids to a maximum of 0.2 mg/kg/body weight. (3) Patients must have had at least three lines of therapy for chronic GVHD prior to hCG therapy (including the contemporarily given medication as steroids and calcineurin inhibitor). (4) Visits and blood examinations were performed two-weekly. (5) Responses to GVHD had to be undertaken at baseline and after 8 weeks of treatment with hCG. Responses were not scored for sites of ocular or oral chronic GVHD, because topical therapy was permitted during hCG treatment. (6) Skin GVHD was evaluated as percentage change in the total skin score (TSS) after 8 weeks of treatment compared with baseline via the use of the validated ordinal 50-point whole-body scoring system. Use of TSS has been reported earlier in studies about extracorporeal photopheresis and IL 2 for treatment of chronic GVHD.
11,12 (7) Patients had given a written informed consent to this experimental therapy and offlabel use of hCG and to all aspects of the stem cell transplantation procedure in accordance to the standards of our department, which are in accordance with the standards of Good Clinical Practice and the Declaration of Helsinki. (9) No change of concurrently used agents for chronic GVHD in the last 6 weeks before the beginning of hCG therapy was documented. hCG was purchased from Ferring, Germany, which did not have any input into the manuscript content or the decision to submit the manuscript for publication. All patients received a myelo-ablative conditioning regimen prior to transplantation and received glucocorticoids as first-line therapy for GHVD and continued medication with calcineurin inhibitors. The medical histories of the patients are summarized in Table 1  and Table 2 .
Application, dose and treatment time of hCG hCG at a dose of 187.5 IU was administrated daily for 8 weeks subcutaneously. hCG was bought in vials of 1500 IU/mL. The dose of 187.5 represents one eighth of 1 mL vials with 1500 IU. This dose is considered as low dose when compared with doses of 5000-10 000 IU of hCG used before in vitro fertilization.
Evaluation of chronic GVHD symptoms
Chronic GVHD symptoms of the skin were assessed clinically using the TSS score. Intestinal, hepatic, neuronal GVHD symptoms and GVHD of the mouth were assessed according to the NIH criteria for chronic GHVD. The assessment of intestinal GVHD was performed endoscopically only including histological examinations.
Laboratory analysis
Flow sorting of immune cell-protocol-specified immunophenotypic analyses were performed at baseline, after 2 and 6 weeks of treatment with hCG in one patient. . Plasma from whole blood (100 μl, 15% EDTA) was incubated with the fluorophore-conjugated monoclonal antibodies anti-CD3 ECD (clone UCHT1, Beckmann Coulter, Krefeld, Germany), anti-CD4 PE (clone 13B8.2, Beckmann Coulter), anti-CD25 PC5 (clone B1.49.9, Beckmann Coulter), anti-CD45 FITC (clone J.33, Beckmann Coulter) and anti-CD127 PC7 (clone R34.34, Beckmann Coulter). The samples were washed and lysed using a TQ-Prep device (Beckmann Coulter), and analyzed using the Cytomics FC 500 with CXP Acquisition Software Version 2.2 (Beckmann Coulter).
IL10 cytokine was quantified in serum using the OptEIA Kit (BD Bioscience, Heidelberg, Germany) sandwich ELISA according to the manufacturer's instructions. IDO gene and FOXP3 gene expression was measured in PBMC isolated by Ficoll density-gradient centrifugation (Hypaque, GE Healthcare, Hamburg, Germany). RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Expression levels of IDO, FOXP3, GAPDH (as housekeeping gene) were assessed using real-time reverse-transcription PCR (RT-PCR) performed with hybridization probes (TIB MOLBIOL, Berlin, Germany) and primers published (Invitrogen, Darmstadt, Germany) elsewhere.
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Statistics
Values are presented as mean ± s.d. Differences in data between groups were tested by two-tailed unpaired t-test or Mann-Whitney U-test using the SPSS 18 program (SPSS Inc, Chicago, IL, USA).
RESULTS
Overall clinical response
Twelve of 20 patients treated with HCG had an objective partial response during 8 weeks of daily subcutanteous treatment with 187.5 IU of hCG (Table 1) . Responses included gastrointestinal improvements in all involved patients (n = 3); softened skin and subcutaneous tissue ( Figure 1) ; decreased erythema and extent of sclerodermatous, hide-bound skin, improved joint mobility and gait, and resolution of neuropathy. Seven patients had stable disease (four with minor objective responses). Of the 12 responding patients, 8 patients received hCG for an extended period up to 12 weeks. One patient discontinued glucocorticoids after 3 months of hCG therapy. Overall, the glucocorticoid dose was tapered by a mean of 28% (range, 0-100%; P = 0.016).
None of the patients except one had a relapse or progression of chronic GVHD. This single patient had chronic GVHD at five organ sites and had already received five pretreatments without response including anti-T-lymphocyte globulines at two different times. Although GVHD at skin, eye, joints and gastrointestinal sites improved, liver GVHD (histologically confirmed by biopsy) showed progress. This patient died from progressive chronic GHVD and a fungal infection (grade 4 infection according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE)) after retreatment with high-dose steroids. CTCAE grade 4 infection occurred 8 weeks after low-dose hCG treatment and was probably not related to hCG.
Total skin score In 19 patients with skin GVHD the TSS score was evaluated prior to hCG therapy as baseline and after 8 weeks from the beginning of hCG therapy. Twelve of 19 patients showed an improvement with hCG therapy, and experienced a reduction of~25% (median, range 15-55%; P = 0.017) in their TSS from baseline ( Figure 2a) . Adverse effects A subcutaneously applied dose of 187.5 IU hCG induced transient CTCAE grade 2 constitutional symptoms (fever, malaise and flush) in 11 of 20 treated patients. Grade 1 enlargement of the breasts (gynecomastia) occurred in three male and nine female patients (Table 1 ). Another adverse event that was possibly related to hCG included reversible and asymptomatic CTCAE grade 4 hypertriglyceridemia (in one patient trigylceride levels were >1000 mg/dL). In this patient the hCG therapy was stopped transiently until triglyceride levels fell under 500 mg/dl and hCG treatment restarted. HCG treatment did not induce any level of leukopenia, neutropenia, thrombocytopenia, hepatic or renal dysfunction in any patient.
IDO, IL 10, T regulatory cells and hCG serum levels
Before hCG treatment and after 6 weeks of treatment IDO and IL 10 serum levels were evaluated. Three weeks of treatment with hCG increased the median IDO expression by sevenfold in PMNCs from the pretreatment baseline (n = 12; P = 0.001) as shown in Figure 2c . IL 10 levels, measured in 11 patients, increased up to 100% in serum after hCG treatment at median (P = 0.048) (Figure 2d) . Further, an expansion of Treg cell population also associated with the induction of tolerance was measured in one patient and identified as CD25med-highCD127low cells in the CD4 gate after 2 weeks. In concordance, FOXP3 gene expression increased simultaneously by up to 50% in PBMNCs of this patient, suggesting a Treg cell expansion.
The serum concentration resulting from low-dose hCG treatment measured 2 weeks after the beginning of hCG therapy ranged between 11 and 27 mIU/mL in patients, which is similar to the early stages of pregnancy (11 or 12 days of pregnancy). 14 pointed out in 1953 that the self-nonself model predicts that mothers should reject their fetuses, it has often been speculated that the allogeneic fetus is protected from attack by its mother's immune system by a naturally occurring molecule. 14, 15 HCG might be a candidate for such a naturally occurring immunemodulating drug. This idea is supported by numerous reports describing improvement in auto-inflammatory diseases, such as Crohn's disease or multiple sclerosis, during pregnancy, when circulating hCG levels are naturally high. [16] [17] [18] Abbreviations: ECP = extracorporeal photopheresis; f = denotes female; GI = gastrointestinal tract; m = male; MMF = mycophenolate mofetil; PUVA = photo therapy with UVA; tacro = tacrolimus; Pred = prednisolone; MR = marginal response; NC = no change; TSS = total skin score; UPN = unique patient number.
DISCUSSION
Since Medawar
Human chorionic gonadotropin in GVHD AH Elmaagacli et al Considering the contemporary medication such as steroids and calcineurin inhibitor, low-dose hCG was applied successfully as fourth-or fifth-line treatment in 8 male and 12 female patients with glucocorticoid-refractory or intolerant chronic GVHD. Patients with GVHD of the skin improved significantly after hCG therapy, and experienced a reduction of~25% (at average) in their TSS, respectively. Twelve of 20 patients treated with HCG had an objective partial response after 8 weeks of hCG treatment (Table 1) . Responses included gastrointestinal improvements, softened skin and subcutaneous tissue (Figure 1) , decreased erythema and extent of sclerodermatous, hidebound skin, improved joint mobility and gait, and resolution of neuropathy. Many patients with chronic GVHD had advanced fibrotic and sclerotic skin manifestations previously considered to be irreversible. However, improvement of sclerodermatous chronic GVHD has been described in a previously reported study exploring extracorporeal photopheresis as a treatment for GVHD. 11 Although the extracorporeal photopheresis procedure is often well tolerated, it is time-consuming, expensive and not beneficial for all patients with GVHD. Twelve of the patients presented here also received extracorporeal photopheresis, but without any clinical improvement.
Treatment with hCG has been previously linked to modulating immune responses. In a prospectively performed study in 34 women treated with high-dose hCG as preconditioning therapy for in vitro fertilization, we found a significantly increased IDO gene expression in PBMNCs, IL10 levels in serum and expansion of the Treg cell population. Our observed changes in immune modulation here are in line with this previous report. 3 Thus, we found a strong increase in IDO expression in PMNCs (sevenfold, at median, n = 12) and in IL10 serum levels (twofold, at median, n = 11) after 3 weeks of therapy with hCG. Further, an expansion of Treg cell population was measured in one patient and identified as CD25med-highCD127low cells in the CD4 gate after 2 weeks of therapy with hCG. Concordantly, increasing numbers of Treg cells in the fetal-maternal interface induced by hCG expression during early pregnancy was also observed by Schumacher et al. 19 IDO has been reported to induce tolerance in several animal models for GVHD, and has also been implicated in maternal-fetal acceptance. 4, 5 Treg, IDO and IL10 are known factors for the induction of immune tolerance as shown in the patho-physiology model for acute GVHD given by Harris et al. [20] [21] [22] [23] The reason to use low-dose hCG was based on the idea that symptoms of auto-inflammatory disease relieve very early in pregnancy. The dose of 187.5 IU used corresponds to the 11th or 12th day of pregnancy and was first aimed as starting dose. However, due to the fact that with this dose clinical response was achieved, no further dose escalation was performed. Nevertheless, a dose-finding study is strongly recommended for the future.
Interestingly, low hCG levels are also detected regularly in cord blood grafts, which are associated with a lower incidence of acute GVHD compared with peripheral stem cell or BM grafts. 24 It is speculative whether these low concentrations of hCG in cord blood grafts might have immune-modulating effects resulting in a reduced incidence of acute GVHD after cord blood transplants as is shown here for low-dose therapy of hCG for chronic GHVD. 25, 26 Based on these studies and based on the experiences from pregnancies of women in which high hCG serum levels are detected regularly, hCG therapy is safe and produces only mild side effects comparable to those seen during early pregnancy. Especially, the rare incidence of expected severe opportunistic infections of a low-dose hCG therapy makes this naturally occurring immune-modulating drug attractive as GHVD prophylaxis or therapy for allogeneic transplants. However, current treatment regimens for severe GVHD produce unsatisfactory results in patients, and hCG appears to be a suitable candidate for improving treatment in this patient group. Our encouraging results warrant prospective evaluation of hCG treatment in a larger cohort of patients with GVHD.
